News Releases

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

September 14, 2021

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

September 7, 2021

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

August 30, 2021

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

August 25, 2021

Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative

August 23, 2021

Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

August 18, 2021

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic

May 26, 2021

Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application

May 20, 2021

Latest News & Events

Aug 25, 2025

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read More...

Aug 20, 2025

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Read More...

Aug 18, 2025

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Read More...